Merck KGaA (FRA:MRK)‘s stock had its “buy” rating restated by research analysts at UBS Group in a research report issued to clients and investors on Monday, www.boersen-zeitung.de reports.

Several other analysts have also recently weighed in on MRK. JPMorgan Chase & Co. set a €100.00 ($119.05) target price on shares of Merck KGaA and gave the company a “neutral” rating in a report on Tuesday, December 12th. Berenberg Bank set a €116.00 ($138.10) target price on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, November 23rd. Bank of America set a €95.00 ($113.10) target price on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, December 6th. Nord/LB set a €98.00 ($116.67) target price on shares of Merck KGaA and gave the company a “neutral” rating in a report on Friday, December 8th. Finally, Morgan Stanley set a €98.00 ($116.67) target price on shares of Merck KGaA and gave the company a “neutral” rating in a report on Friday, December 1st. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of €107.57 ($128.06).

Shares of Merck KGaA (FRA MRK) traded up €0.50 ($0.60) on Monday, hitting €91.76 ($109.24). 234,878 shares of the stock traded hands. The firm has a market capitalization of $11,860.00 and a PE ratio of 21.49. Merck KGaA has a 1-year low of €87.33 ($103.96) and a 1-year high of €115.00 ($136.90).

COPYRIGHT VIOLATION NOTICE: “Merck KGaA (MRK) Given “Buy” Rating at UBS Group” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/15/merck-kgaa-mrk-given-buy-rating-at-ubs-group.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.